Celtaxsys
  • DRUG PIPELINE
    Celtaxsys is focused on developing new drugs to treat inflammatory diseases. Celtaxsys’ clinical program includes CTX-4430, a first-in-class oral LTA4 Hydrolase inhibitor for treatment of pulmonary inflammation associated with Cystic Fibrosis.
  • CYSTIC FIBROSIS
    One of the most frequent recessive genetic diseases, affecting 1 in 2,500 individuals. Although the genetic defect in CF causes malfunction in many organs and tissues, it is most often exacerbations and the accompanying inflammatory respiratory distress that results in hospitalization or life threatening events.
  • INNATE IMMUNITY
    Innate Immunity is an ancient protective system that is active from birth and serves as our first line of defense. This system is now known to be important in both promoting and resolving inflammation. Celtaxsys is developing new ways to modulate innate immunity to reduce inflammation and promote resolution.
  • THE NEUTROPHIL
    The neutrophil is one of the most mobile and potentially destructive cells in the body, and neutrophil dysfunction is a key contributor to many inflammatory diseases. Celtaxsys is developing innovative ways to selectively control and correct neutrophil function.
Celtaxsys is a clinical-stage drug discovery and development company focused on novel
therapeutics that treat inflammatory disease by controlling innate immunity.
Our lead drug candidate, CTX-4430, is currently undergoing clinical trials for Cystic Fibrosis

Celtaxsys
Copyright © 2014 Celtaxsys, Inc., Atlanta, GA

 

 

 

more Innate Immunity  is an ancient protective system that is active from birth and serves as our first line of defense against infection. This system is now known to be important in both promoting and resolving inflammation. Celtaxsys is developing new ways to modulate innate immunity to reduce inflammation and promote resolution. more The Neutrophil  is one of the most mobile and potentially destructive cells of any cell in the body. Celtaxsys is pioneering a new way of telling neutrophils to move away from an inflamed area, a process called immunorepulsion. more An Inflammatory Disease  is a condition caused largely by improper regulation of the immune system. Some well-known examples include Multiple Sclerosis, Cystic Fibrosis, and Inflammatory Bowel Disease. Celtaxsys is discovering new medicines to treat these and other inflammatory diseases. Drug Pipeline Clinical Trials Home About Science News Contact Investor Resource

The Neutrophil inflammatory Disease neutrophil innate immunity FreeWebSubmission.comSonicRun.com More More Celtaxsys to present Phase 1 Data at the North American Cystic Fibrosis Conference in Salt Lake City, October 17-19, 2013 Mr. Khalil Barrage appointed to Celtaxsys Board of Directors New Researchers appointed to Celtaxsys Medical Advisory Panel